Luminex announced that it has received FDA clearance for its xTAG Gastrointestinal Pathogen Panel (GPP), a comprehensive molecular diagnostic assay that tests for >90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single assay.
xTAG GPP is a multiplexed nucleic acid-based amplification assay that simultaneously tests for 11 of the most common gastroenteritis causing viruses, bacteria, and parasites. The panel includes: Campylobacter, Clostridium difficile Toxin A/B, Escherichia coli O157, Enterotoxigenic E. coli (ETEC) LT/ST, Shiga-like toxin producing E. coli (STEC) stx1/stx2, Salmonella, Shigella, Rotavirus A, Norovirus GI/GII, Giardia lamblia and Cryptosporidium. Detection and identification of specific gastrointestinal microbia can aid in the diagnosis of infection and the investigation of acute gastroenteritis outbreaks.
The assay uses the proprietary Luminex xTAG Technology and the xMAP Technology platform to detect multiple targets in a single sample.
For more information call (888) 219-8020 or visit www.luminexcorp.com/gpp